Biond Biologics is an innovative biotech company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform to treat "undruggable" diseases.
Location: Israel, North District, Nahariah
Employees: 11-50
Total raised: $32M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Deep Insig... | deepinsigh... |
| - | Israel Bio... | ibf.fund |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.11.2021 | Series C | $15M | - |
| 08.01.2019 | Series B | $17M | - |
Mentions in press and media 3
| Date | Title | Description |
| 04.07.2024 | Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial | MISGAV, Israel, June 24, 2024 /PRNewswire/ — Biond Biologics Ltd. (“Biond” or the “Company”), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of bi... |
| 03.11.2021 | Biond Biologics Announces Closing of $15 Million Series C Financing | MISGAV, Israel, Nov. 3, 2021 /PRNewswire/ -- Biond Biologics Ltd., a private, clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, announced to... |
| 08.01.2019 | Biond Biologics Raises $17M in Series B Financing | Biond Biologics Ltd., a Misgav, Israel-based biotechnology company developing novel immunotherapies for cancer and autoimmune diseases, closed a $17m Series B financing. The financing and due diligence were led by Israel Biotech Fund and Ha... |